(OLE) trial – – Vocal biomarker speech latency data from RECOVER trial reinforce brilaroxazine’s improvement on negative ...

The U.S. Food and Drug Administration has approved Cobenfy (xanomeline and trospium chloride), a first-in-class muscarinic ...

A multitude of genes have been linked to the development of Alzheimer's disease. Specifically how those genes might influence ...

The FDA added a warning to the label of esketamine nasal spray (Spravato), noting that long-term cognitive and memory ...

A new study links hallucinogen-related emergency department visits to a 21-fold increased risk of schizophrenia compared to ...

Individuals with emergency department visits involving hallucinogen use are at high risk of developing schizophrenia, ...

Its pipeline includes treatments for bipolar depression, agitation in Alzheimer’s disease, schizophrenia and Parkinson’s ...

Psychedelics have been growing in popularity across North America for recreational and therapeutic use, with celebrities like ...

AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...

Some people who took a new schizophrenia drug for a year improved with only a few side effects, but many dropped out of the ...

Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...

AbbVie Inc. shares fell the most in three years after two mid-stage trials of its drug to treat schizophrenia failed to meet ...